Structural basis for the specific inhibition of heterotrimeric G q protein by a small molecule Heterotrimeric GTP-binding proteins (G proteins) transmit extracellular stimuli perceived by G protein-coupled receptors (GPCRs) to intracellular signaling cascades. Hundreds of GPCRs exist in humans and are the targets of a large percentage of the pharmaceutical drugs used today. Because G proteins are regulated by GPCRs, small molecules that directly modulate G proteins have the potential to become therapeutic agents. However, strategies to develop modulators have been hampered by a lack of structural knowledge of targeting sites for specific modulator binding. Here we present the mechanism of action of the cyclic depsipeptide YM-254890, which is a recently discovered G q -selective inhibitor. YM-254890 specifically inhibits the GDP/GTP exchange reaction of α subunit of G q protein (Gαq) by inhibiting the GDP release from Gαq. X-ray crystal structure analysis of the Gαqβγ-YM-254890 complex shows that YM-254890 binds the hydrophobic cleft between two interdomain linkers connecting the GTPase and helical domains of the Gαq. The binding stabilizes an inactive GDP-bound form through direct interactions with switch I and impairs the linker flexibility. Our studies provide a novel targeting site for the development of small molecules that selectively inhibit each Gα subunit and an insight into the molecular mechanism of G protein activation.
G protein | crystal structure | specific inhibitor H eterotrimeric guanine nucleotide-binding proteins (G proteins) serve as critical relays that transmit extracellular stimuli perceived by G protein-coupled receptors (GPCRs) at the cell surface to intracellular signaling cascades (1-3). Heterotrimeric G proteins comprise three subunits, α, β, and γ. The Gα subunit conserves the Ras-like GTPase domain that is essential for hydrolyzing GTP to GDP. In an in vivo resting state, the Gα subunit usually exists in the GDP-bound state and forms a trimer with the β and γ subunits. A ligand-activated GPCR acts as a guanine nucleotide exchange factor (GEF) that stimulates exchange of bound GDP for GTP on the Gα subunit. GTP binding alters three flexible regions, switches I, II, and III, of Gα, leading to Gβγ dissociation and the subsequent binding of Gα and Gβγ to downstream effectors. Signal termination is achieved by GTP hydrolysis, resulting in the reformation of an inactive heterotrimer.
GPCR-mediated signal transduction controls a wide variety of organ functions through multiple signaling pathways (3). The 15 human genes encoding Gα subunits are categorized into four subfamilies: Gα s , Gα I , Gα q , and Gα 12 . The multiplicity of receptor-G protein interactions makes it difficult to analyze the intracellular signaling network. The most straightforward approach is to apply a specific inhibitor or activator for one type of G protein. However, until now, availability of small molecules has been limited to a subset of Gα subunits. Strategies to develop small molecule inhibitors have been hampered by a lack of structural information about the inhibitor binding site on the molecular surface.
To identify such an inhibitor binding site, we focused our studies on the cyclic depsipeptide YM-254890, which was isolated from Chromobacterium sp. QS3666 as an inhibitor of ADPinduced platelet aggregation (4). YM-254890 strongly inhibits intracellular calcium ion mobilization and serum response element (SRE)-mediated transcription stimulated by several receptors coupled to G q , but not those coupled to G i , G s , or G 15 (5) . YM-254890 also exhibited antithrombotic and thrombolytic effects in an electrically induced carotid artery thrombosis model in rats (6) . YM-254890 is the first and only compound that specifically inhibits G q signaling. Accordingly, it is an invaluable tool for analyzing G protein activation and G q -mediated cell responses. However, the details of the inhibitory mechanism of YM-254890 remain to be revealed.
In this study, we carried out the biochemical characterization of YM-254890 using purified G proteins in vitro and determined the X-ray crystal structure of the heterotrimeric G q protein complexed with YM-254890. Our results revealed a unique inhibitory mechanism by which YM-254890 selectively blocks GDP release from the G q protein.
Results
Specific Inhibition of G q Family Members by YM-254890. Previously, it was reported that YM-254890 blocks agonist-induced GTPγS binding to G q∕11 in crude cell membranes (5) . This finding suggests the possibility that YM-254890 directly binds to Gα q and inhibits the GDP/GTP exchange. To test this, we first performed an in vitro ½ 35 SGTPγS binding assay using purified Gα q protein. YM-254890 blocked spontaneous GTPγS binding to Gα q in a concentration-dependent manner, suggesting a stoichiometric interaction between Gα q and YM-254890 ( Fig. 1 A and B) . On the other hand, YM-254890 had no effect on the spontaneous GTPγS binding to Gα s , Gα i1 , Gα o , and Gα 13 (Fig. S1 ). GTP binding to GDP-bound Gα consists of two reactions: dissociation of bound GDP and binding of GTP to nucleotide-free Gα. The dissociation of GDP is a rate-limiting step in the GDP/GTP exchange reaction. We investigated the effect of YM-254890 on GDP dissociation from Gα q . ½ 3 HGDP was preloaded on Gα q , and ½ 3 HGDP released from Gα q was analyzed in the presence or absence of YM-254890. YM-254890 blocked GDP dissociation from Gα q in a concentration-dependent manner ( Fig. 1 C and D) , indicating that YM-254890 acts as a Gα q -specific guanine nucleotide dissociation inhibitor (GDI).
Aluminum fluoride (AlF 4 − ) is known to activate Gα proteins by mimicking the γ-phosphate of GTP in the presence of GDP (7, 8) . Thus, the addition of AlF 4 − induces conformational changes in Gα proteins from the GDP-bound inactive form to the GDP-AlF 4 − -bound active state (9, 10). YM-254890 inhibited the AlF 4 − -induced conformational change in Gα q and Gα 14 but not Gα 16 (Fig. S2 ). In Fig. S2 , we used ectopically expressed Gα proteins in lysates from mammalian cells, because both Gα 14 and Gα 16 proteins were difficult to purify. The results of a previous study (5) and those of our studies indicate that YM-254890 selectively inhibits Gα q , Gα 11 , and Gα 14 among mammalian Gα members.
To examine whether YM-254890 inhibits Gα q bound to Gβγ, we prepared heterotrimer His-Gα i/q β 1 γ 2 C68S (henceforth, referred to as His-Gα i/q βγ), which contains His-Gα i/q , Gβ 1 , and nonprenylated His-Gγ 2 C68S. Gα i/q is a soluble and functional Gα q chimera in which the wild-type N-terminal helix was replaced with that of Gα i1 (11) . We compared the YM-254890 sensitivity of monomeric His-Gα i/q and heterotrimeric His-Gα i/q βγ by using the ½ 35 SGTPγS binding assay. YM-254890 inhibited the GTPγS binding to His-Gα i/q βγ as well as Gβγ-free His-Gα i/q (Fig. S3 ).
Overall Structure of Heterotrimeric G Protein Complexed with YM-254890. To clarify the molecular basis of the YM-254890 action, the crystal structure of Gα i/q βγ bound to YM-254890 was determined at a 2.9 Å resolution (Table S1 ). The structure reveals the heterotrimer in which Gγ 2 -bound Gβ 1 forms extensive contacts with Gα i/q , which consists of the N-terminal helix as well as the GTPase and helical domains ( Fig. 2A) . The major α/β interface covers the N-terminal helix and switch II from the GTPase domain, but not the helical domain, of Gα i/q . GDP binds to a cleft between the GTPase and helical domains without contacting Gβγ. These structural characteristics are basically similar to the other reported G protein heterotrimer structures (12, 13) . YM-254890 docks into the cleft between Linker 1 and Switch I (Linker 2), which connect the GTPase and helical domains. To our knowledge, this cleft has never been described as a critical contact site with other molecules, including Gα effectors (11, 14) , Gβγ (12, 13), GoLoco (15), GPCRs (16), or GPCR-mimic peptides (17) . A structural comparison of our YM-254890-bound Gα i/ q βγ with the inhibitor-free heterotrimers containing Gα i1 or Gα t/i1 (12, 13) suggested a slightly different configuration of the helical domain against the GTPase domain (Fig. S4A) . Although a crystal packing effect can not be excluded, this rotation of the helical domain relative to the GTPase domain may represent a basic property of Gα q rather than a conformation induced by the binding of YM-254890. The configuration of the two domains of YM-254890-bound Gα i/q appears to overlap with the active form of Gα i/q (11, 14) (Fig. S4B) . It is known from the structures of GDP-bound and GTP-bound Gα t that the orientation of the helical domain is unaffected by nucleotide exchange; the structures are quite similar except for the three switch regions. Furthermore, there is precedence for a difference of the configuration of the two domains among Gα subfamilies in the structures reported for Gα i1 and Gα t (9) . Switches I-III of Gα i/q preserved the canonical GDP-bound conformation (Fig. S4C) .
YM-254890 consists of a cyclic backbone and an additional subregion (red region in Fig. 2C ) with seven amide bonds. YM-254890 in our complex may exhibit a combination of cisor trans-amide bond conformations identical to the major conformer suggested by a previous NMR analysis in solution (18) and display an overall conformation of a folded V-shape, which is in part stabilized by intramolecular hydrogen bonds (Fig. 2D and  Fig. S5 ). The compact form of YM-254890 has 1047 Å 2 of the total solvent accessibility area, of which 52% (543 Å 2 ) is masked by direct contact with Gα i/q (Fig. 2B ).
Binding Mode of YM-254890 to G Protein. The interface between YM-254890 and Gα i/q comprises the α1 helix and β2 strand from the GTPase and the αA helix from the helical domains in addition to the two interdomain linkers: Linker 1, connecting the α1 and αA helices, and Switch I (Linker 2), connecting the αF helix and the β2 strand (Fig. 3A) . The inhibitor-protein interactions are summarized in Fig. 4A . Thirteen residues of the binding cleft participate in nonpolar may contacts with YM-254890. At the bottom of the cleft, the aromatic phenyl group of YM-254890 D-Pla docks into a small hydrophobic pocket (Fig. 4A) (Fig. 3 B and C) .
To validate the contribution of these resides to the binding affinity, we generated Gα q -point mutants and measured the YM-254890 sensitivity of each Gα q mutant. Using the trypsin protection assay, we first confirmed that each Gα q mutant has the capacity to undergo a proper conformation change (Fig. S6) . (Fig. 3D) . These intimate interactions cannot be retained in the GTP-bound form, whose Switch I is shifted approximately 2 Å away from the YM-254890-bound cleft (19, 20) . In sharp contrast to Switch I (Linker 2), Linker 1 lacks most direct contacts with YM-254890. Instead, the salt bridge between Arg 60 from the GTPase domain (α1 helix) and Asp 71 from the helical domain (αA helix), the Arg-Asp pair, would mediate the Linker 1-inhibitor interactions by forming multiple hydrogen bonds ( Fig. 3E and Fig. S7 ). The terminal guanidium group of Arg 60 would be essential for these interactions and contribute to the stabilization of the V-shaped ring of the inhibitor. Mutation of Arg 60 with a lysine residue resulted in approximately 620-fold less sensitivity to YM-254890 (Fig. 4B) .
Discussion YM-254890 exhibits exquisite substrate specificity for Gα q , Gα 11 , and Gα 14 . Our sequence alignment reveals that the Gα residues directly interacting with the inhibitor are completely conserved in all YM-254890-sensitive Gα q , Gα 11 , and Gα 14 but not in other Gα members (Fig. 5) . In particular, Gα 15 and Gα 16 conserve all the key residues except Switch I. Our Switch I mutations, I190N and P193C, which replace each Gα q residue with the corresponding residue in Gα 15 and Gα 16 , respectively, reduce inhibitor sensitivity (Fig. 4B) . Thus, we speculate that, in principle, Switch I would ensure the specificity. Other Gα members display sequence diversity in regions other than Switch I. Such an example is Gα i1 , which possesses lysine instead of the key residue Arg 60 . The R60K mutation severely reduces the activity, as already described (Fig. 4B) .
YM-254890-mediated stabilization of both interdomain linkers, Linker 1 and Switch I (Linker 2), directly accounts for the repression of the GDP release from Gα q ( Fig. 1 C and D) and, thereby, the repression of the exchange with GTP ( Fig. 1  A and B) . A large body of experimental evidence (16, (21) (22) (23) (24) (25) supports the importance of the rearrangement of the GTPase and helical domains of Gα to create the necessary route for GDP dissociation. In particular, two flexible interdomain linkers appear to act together as a hinge during the opening of the helical domain away from the GTPase domain. A site-directed spin-labeling study showed that a ligand-activated GPCR triggers the conformational change in Switch I (21) . A previous mutation study also indicated that the flexibility of interdomain linkers controls the GDP release rate of Gα (25) . In our structure model, YM-254890 forms a cone-like structure with its phenyl group at the head and was stuck deeply into the cleft between both interdomain linkers. As described above, YM-254890 should stabilize Switch I in the inactive GDP-bound conformation through direct interaction (Fig. 3D) . The Linker 1-YM-254890 interaction with multiple hydrogen bonds would also contribute to the stabilization of interdomain linkers (Fig. 3E and Fig. S7) . Thus, YM-254890 may repress GDP release by docking into the cleft to reduce a hinge motion of interdomain linkers that are necessary for the rearrangement of the GTPase and helical domains (Fig. 6 A and C) . In contrast, it has been shown that the GoLoco motif, which is known to exert GDI activity against G i subfamily members, acts as a "clamp" by contacting both the GTPase and helical domains to restrict the domain rearrangement ( Fig. 6 B and D) (15, 26) .
The unique binding mode of YM-254890 to G q is reminiscent of that of the "interfacial inhibitor," which is an alternative to a competitive inhibitor in the development of innovative therapeutics (27, 28) . The interfacial inhibitor binds to two macromolecules (protein-protein or protein-nucleic acid) and forms a dead-end complex. Brefeldin A is a typical interfacial inhibitor that stabilizes the abortive complex of Arf and Arf-GEF, inhibiting Arf activation by its GEF (29) . In our current model, YM-254890 binds to a cleft between the GTPase and helical domains within one molecule and restricts the conformational rearrangement of these domains. We propose that YM-254890 should be categorized as a unique type of inhibitor, which fixes a domaindomain interface of one macromolecule by binding to hinge regions connecting two intramolecular domains. In some signaltransduction proteins, the interdomain rearrangement is important for the regulation of their molecular functions. The molecular basis of YM-254890 action provides the possibility that a pocket formed by hinge regions becomes a unique site for inhibitor binding.
More recently, constitutive activation of the heterotrimeric G protein α subunit with somatic mutations has been found in uveal melanoma and blue naevi (30) . YM-254890 suppresses the oncogenic mutant-induced transcriptional activation (5), suggesting a potential YM-254890 application in cancer in addition to several other diseases. The nucleotide exchange reaction of some α subunits, Gα q , Gα i1 , and Gα o , is promoted by Ric-8A (31). Interest- (Fig. S6) . Fig. 5 . Sequence alignment of G protein α subunits around the YM-254890 binding site. Linker 1 and Switch I regions are outlined in black. The predicted secondary structure is represented by orange squares and a purple arrow for the α helices and the β strand, respectively. The residue numbering is based on Gαq. The residues that appear to directly interact with YM-254890 are shown on a red background. In particular, the residues that form the hydrophobic pocket, which would bind to the phenyl group of YM-254890, are marked with a blue background. Conserved residues at these positions in YM-254890-insensitive Gα are shown on a light-red or light-blue background. These residues are completely conserved only in YM-254890-sensitive Gαq, Gα11, and Gα14.
ingly, YM-254890 also inhibits the Ric-8A-mediated exchange reaction of Gα q (32) , which is consistent with the notion that the inhibitor directly binds to Gα q . Cholera (33) , pertussis (34) , and Pasturella multocida (35) toxins are well known modulators of G protein activity. As a G q -specific inhibitor, YM-254890 should be a useful addition to the tools available to analyze diverse G protein signaling pathways. A close look at the previously reported Gα structures shows that each α subunit preserves the interdomain cleft, which is similar to that of our structure but displays unique surface shapes and properties. This observation suggests that YM-254890 derivatives or YM-254890-mimic compounds could be developed for the specific inhibition of each Gα.
Materials and Methods
Protein Expression and Purification. Baculoviruses encoding His-Gαi/q and His-Gγ2C68S were generated using the Bac-to-Bac baculovirus expression system (Invitrogen). Baculoviruses encoding Gαq, Gα13, Gβ1, and His-Gγ2 were kindly provided by Tohru Kozasa (University of Illinois at Chicago). Purification of His-Gαi/q and Gαi/qβ1γ2C68S from baculovirus-infected High Five cells was performed as previously described (11) , with the addition of an anion-exchange chromatography step before a final gel-filtration step. For crystallization, Gαi/qβ1γ2C68S was finally concentrated to 40 mg∕mL using Centricon YM-30. Purification of Gαq, Gαi1, and Gα13 from baculovirusinfected Sf9 cells was performed as previously described (36) . His-Gαo was purified from BL21(DE3) cells using Ni-NTA agarose (QIAGEN). Gαs was purified from BL21(DE3) cells as previously described (37) .
Crystallization. Gαi/qβγ (375 μM, 28 mg∕mL) mixed with 2 mM YM-254890 in a buffer containing 20 mM Hepes-NaOH pH 8.0, 100 mM NaCl, 1 mM MgCl 2 , 2 mM DTT, 0.4 mM GDP, and 4% (v∕v) DMSO was used for crystallization. Crystallization screening was carried out by the vapor-diffusion method at 20°C using commercial screening kits (Nextal Biotechnologies). The protein was mixed in a 1∶1 ratio with the reservoir solution. Crystallization conditions were subsequently optimized by the sparse matrix method. The prismatic crystal of the Gαi/qβγ-YM-254890 complex was obtained under conditions that included 7% PEG 4,000, 70 mM acetate-NaOH pH 5.1, and 30% (v∕v) glycerol.
GTPγS Binding Assay. GTPγS binding of the purified Gα was measured using a filter-binding method. The spontaneous GTPγS binding of Gαq and Gαi1 was promoted in the presence of ðNH 4 Þ 2 SO 4 , as previously described (38) . Briefly, purified Gα (100 nM) was preincubated with YM-254890 for 3 min at 20°C in assay buffer A (50 mM Hepes-NaOH pH 7.5, 1 mM EDTA, 1 mM DTT, 0.9 mM MgSO 4 , and 0.05% Genapol C-100). Reactions were started by the addition of 10 μM ½ 35 SGTPγS (10;000 cpm∕pmol) and 300 mM ðNH 4 Þ 2 SO 4 . The GTPγS binding of Gαs and Gαo was performed in assay buffer B (20 mM Hepes-NaOH pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 10 mM MgSO 4 , and 0.05% Lubrol-PX) (31) . The GTPγS binding of Gα13 was performed in assay buffer C (50 mM Hepes-NaOH pH 7.6, 1 mM EDTA, 1 mM DTT, 0.5 mM MgSO 4 , and 0.05% Lubrol-PX) (39) . Reactions of Gαq and Gαs were carried out at 20°C, whereas those of Gαi1, Gαo, and Gα13 were performed at 25°C. The reactions were stopped by the addition of an ice-cold stop buffer (20 mM Tris-HCl pH 7.7, 100 mM NaCl, 2 mM MgSO 4 , 0.05% Genapol C-100 or Lubrol-PX, and 1 mM GTP), and the mixtures were filtered through nitrocellulose membranes. The membranes were washed twice with an ice-cold wash buffer (20 mM Tris-HCl pH 7.7, 100 mM NaCl, and 2 mM MgSO 4 ) and air-dried.
GDP Dissociation Assay. Gαq (100 nM) was incubated with 2 μM ½ 3 HGDP (10;000 cpm∕pmol) for 18 h at 20°C in assay buffer A with 50 mM ðNH 4 Þ 2 SO 4 . Approximately 25% of Gαq incorporated the radiolabeled nucleotide. The reaction mixtures were then mixed with the same volume of an assay buffer containing an excess of unlabeled GDP (1 mM), DMSO or YM-254890, and 750 mM ðNH 4 Þ 2 SO 4 to monitor the dissociation of ½ 3 HGDP. The reactions were stopped by the addition of an ice-cold wash buffer, and the mixtures were filtered.
Luciferase Assay of the SRE-Mediated Transcription. 293T cells were seeded on a 48-well plate and transfected using Lipofectamine 2000 (Invitrogen) with pCMV5-Gαq or its mutant plasmids (50 − 70 ng∕well), pCMV5-M1 muscarinic acetylcholine receptor (10 ng∕well), pSRE-Luc (50 ng∕well), pEF-RLuc (0.5 ng∕well), and pCMV5 up to a total of 300 ng∕well of plasmid DNA. YM-254890 was added 20 min after transfection. At 18 h posttransfection, the cells were harvested and subjected to the Dual-Luciferase Reporter Assay System (Promega) using a multilabel plate reader (PerkinElmer). Expression levels of Gαq and its mutants were confirmed by immunoblotting. Firefly luciferase activity derived from pSRE-Luc was normalized to the Renilla luciferase activity derived from pEF-RLuc.
For more information, see SI Materials and Methods.
